Zest Equity
Zest Equity is a venture capital firm based in Dubai, United Arab Emirates. This profile covers what we know about Zest Equity and how founders can get in front of it in 2026.
Zest Equity regularizes access to secondary investing for later-stage venture-backed companies.
- Location
- Dubai, United Arab Emirates
- Founded
- 2021
- Team size
- 11-50
How to pitch Zest Equity
The founders who hear back from Zest Equity lead with traction and a clear ask that matches its stage, not a generic mass email. Build a targeted, verified list, write a personalized note, and track who opens it, all in one place.
Connect with Zest Equity
About this profile
This profile is part of Round Funded, an investor database and outreach platform for founders. It covers 60,000+ active VCs, angels, family offices and accelerators with verified contacts, lets you send pitches from your own Gmail, and includes a free Data Room for your raise. How this data is built.
Cite this page
Round Funded. "Zest Equity." Round Funded investor database, updated October 19, 2026.
Stable URL, it will not change: https://www.roundfunded.com/en/vc/zest-equity
Frequently Asked Questions
What is Zest Equity?
Zest Equity is a venture capital firm based in Dubai, United Arab Emirates. Round Funded tracks its focus, stage, and activity alongside thousands of active investors.
Where is Zest Equity based?
Zest Equity is based in Dubai, United Arab Emirates. You can reach out from anywhere with a pitch that matches its focus.
How do I contact Zest Equity?
Unlock a verified email for Zest Equity and reach out with a personalized pitch on Round Funded. We show only deliverable contacts, so your outreach does not bounce.
What is Round Funded?
Round Funded is an investor database and outreach platform for startup founders. It lists 60,000+ active investors with verified contacts, filtered to recent investment activity, and lets founders send personalized pitches from their own Gmail, track replies, and share a free Data Room. Round+ starts at $99 per month with a 3-day trial.